These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 33578672)

  • 1. Carbapenem Therapeutic Drug Monitoring in Critically Ill Adult Patients and Clinical Outcomes: A Systematic Review with Meta-Analysis.
    Lechtig-Wasserman S; Liebisch-Rey H; Diaz-Pinilla N; Blanco J; Fuentes-Barreiro YV; Bustos RH
    Antibiotics (Basel); 2021 Feb; 10(2):. PubMed ID: 33578672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibiotics for ventilator-associated pneumonia.
    Arthur LE; Kizor RS; Selim AG; van Driel ML; Seoane L
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD004267. PubMed ID: 27763732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of the introduction of real-time therapeutic drug monitoring on empirical doses of carbapenems in critically ill burn patients.
    Fournier A; Eggimann P; Pagani JL; Revelly JP; Decosterd LA; Marchetti O; Pannatier A; Voirol P; Que YA
    Burns; 2015 Aug; 41(5):956-68. PubMed ID: 25678084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beta-Lactam Antibiotic Therapeutic Drug Monitoring in Critically Ill Patients: A Systematic Review and Meta-Analysis.
    Pai Mangalore R; Ashok A; Lee SJ; Romero L; Peel TN; Udy AA; Peleg AY
    Clin Infect Dis; 2022 Nov; 75(10):1848-1860. PubMed ID: 35731853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic drug monitoring of carbapenem antibiotics in critically ill patients: an overview of principles, recommended dosing regimens, and clinical outcomes.
    Joynt GM; Ling L; Wong WT; Lipman J
    Expert Rev Clin Pharmacol; 2023; 16(8):703-714. PubMed ID: 36942827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Systematic Review of the Effect of Therapeutic Drug Monitoring on Patient Health Outcomes during Treatment with Carbapenems.
    Luxton TN; King N; Wälti C; Jeuken LJC; Sandoe JAT
    Antibiotics (Basel); 2022 Sep; 11(10):. PubMed ID: 36289971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. β-Lactam Therapeutic Drug Monitoring in Critically Ill Patients: Weighing the Challenges and Opportunities to Assess Clinical Value.
    Dilworth TJ; Schulz LT; Micek ST; Kollef MH; Rose WE
    Crit Care Explor; 2022 Jul; 4(7):e0726. PubMed ID: 35815181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic drug monitoring-guided continuous infusion of piperacillin/tazobactam significantly improves pharmacokinetic target attainment in critically ill patients: a retrospective analysis of four years of clinical experience.
    Richter DC; Frey O; Röhr A; Roberts JA; Köberer A; Fuchs T; Papadimas N; Heinzel-Gutenbrunner M; Brenner T; Lichtenstern C; Weigand MA; Brinkmann A
    Infection; 2019 Dec; 47(6):1001-1011. PubMed ID: 31473974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ineffectiveness of procalcitonin-guided antibiotic therapy in severely critically ill patients: A meta-analysis.
    Peng F; Chang W; Xie JF; Sun Q; Qiu HB; Yang Y
    Int J Infect Dis; 2019 Aug; 85():158-166. PubMed ID: 31229612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic drug monitoring-based dose optimisation of piperacillin/tazobactam to improve outcome in patients with sepsis (TARGET): a prospective, multi-centre, randomised controlled trial.
    Hagel S; Fiedler S; Hohn A; Brinkmann A; Frey OR; Hoyer H; Schlattmann P; Kiehntopf M; Roberts JA; Pletz MW;
    Trials; 2019 Jun; 20(1):330. PubMed ID: 31171029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial.
    de Jong E; van Oers JA; Beishuizen A; Vos P; Vermeijden WJ; Haas LE; Loef BG; Dormans T; van Melsen GC; Kluiters YC; Kemperman H; van den Elsen MJ; Schouten JA; Streefkerk JO; Krabbe HG; Kieft H; Kluge GH; van Dam VC; van Pelt J; Bormans L; Otten MB; Reidinga AC; Endeman H; Twisk JW; van de Garde EMW; de Smet AMGA; Kesecioglu J; Girbes AR; Nijsten MW; de Lange DW
    Lancet Infect Dis; 2016 Jul; 16(7):819-827. PubMed ID: 26947523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review.
    Sime FB; Roberts MS; Peake SL; Lipman J; Roberts JA
    Ann Intensive Care; 2012 Jul; 2(1):35. PubMed ID: 22839761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients.
    Cortegiani A; Russotto V; Maggiore A; Attanasio M; Naro AR; Raineri SM; Giarratano A
    Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD004920. PubMed ID: 26772902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double carbapenem as a rescue strategy for the treatment of severe carbapenemase-producing Klebsiella pneumoniae infections: a two-center, matched case-control study.
    De Pascale G; Martucci G; Montini L; Panarello G; Cutuli SL; Di Carlo D; Di Gravio V; Di Stefano R; Capitanio G; Vallecoccia MS; Polidori P; Spanu T; Arcadipane A; Antonelli M
    Crit Care; 2017 Jul; 21(1):173. PubMed ID: 28679413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Choice of therapeutic interventions and outcomes for the treatment of infections caused by multidrug-resistant gram-negative pathogens: a systematic review.
    Nørgaard SM; Jensen CS; Aalestrup J; Vandenbroucke-Grauls CMJE; de Boer MGJ; Pedersen AB
    Antimicrob Resist Infect Control; 2019; 8():170. PubMed ID: 31709047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Current Status and Future Perspectives of Beta-Lactam Therapeutic Drug Monitoring in Critically Ill Patients.
    Novy E; Martinière H; Roger C
    Antibiotics (Basel); 2023 Mar; 12(4):. PubMed ID: 37107043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tigecycline Therapy for Nosocomial Pneumonia due to Carbapenem-Resistant Gram-Negative Bacteria in Critically Ill Patients Who Received Inappropriate Initial Antibiotic Treatment: A Retrospective Case Study.
    Wu X; Zhu Y; Chen Q; Gong L; Lin J; Lv D; Feng J
    Biomed Res Int; 2016; 2016():8395268. PubMed ID: 28044137
    [No Abstract]   [Full Text] [Related]  

  • 18. Right Dose Right Now: bedside data-driven personalized antibiotic dosing in severe sepsis and septic shock - rationale and design of a multicenter randomized controlled superiority trial.
    Roggeveen LF; Fleuren LM; Guo T; Thoral P; de Grooth HJ; Swart EL; Klausch TLT; van der Voort PHJ; Girbes ARJ; Bosman RJ; Elbers PWG
    Trials; 2019 Dec; 20(1):745. PubMed ID: 31852491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic drug monitoring of antiretrovirals for people with HIV.
    Kredo T; Van der Walt JS; Siegfried N; Cohen K
    Cochrane Database Syst Rev; 2009 Jul; (3):CD007268. PubMed ID: 19588422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients?
    Wong G; Sime FB; Lipman J; Roberts JA
    BMC Infect Dis; 2014 Nov; 14():288. PubMed ID: 25430961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.